OTC Markets OTCQB - Delayed Quote USD

Nuo Therapeutics, Inc. (AURX)

Compare
1.5500
+0.1500
+(10.71%)
At close: January 10 at 9:31:33 AM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
1,167.3160
608.5250
112.2500
--
--
Cost of Revenue
257.7980
126.0920
19.2140
--
--
Gross Profit
909.5180
482.4330
93.0360
--
--
Operating Expense
3,390.2240
3,650.7070
3,413.6300
90.6700
378.0590
Operating Income
-2,480.7060
-3,168.2740
-3,320.5940
-90.6700
-378.0590
Net Non Operating Interest Income Expense
-0.8380
-3.1620
-2.1030
--
-48.3900
Other Income Expense
--
--
150.9610
--
335.5790
Pretax Income
-2,480.1940
-3,171.4360
-3,171.7360
-90.6700
-90.8700
Net Income Common Stockholders
-2,480.1940
-3,171.4360
-3,171.7360
-886.2620
7,708.8240
Diluted NI Available to Com Stockholders
-2,480.1940
-3,171.4360
-3,171.7360
-886.2620
7,708.8240
Basic EPS
-0.06
-0.08
-0.08
-0.03
0.30
Diluted EPS
-0.06
-0.08
-0.08
-0.03
0.27
Basic Average Shares
44,272.2420
42,077.8110
40,001.0890
30,296.3760
25,692.2480
Diluted Average Shares
44,272.2420
42,077.8110
40,001.0890
30,296.3760
27,312.1760
Total Operating Income as Reported
-2,480.7060
-3,168.2740
-3,320.5940
-90.6700
-378.0590
Total Expenses
3,648.0220
3,776.7990
3,432.8440
90.6700
378.0590
Net Income from Continuing & Discontinued Operation
-2,480.1940
-3,171.4360
-3,171.7360
-90.6700
-90.8700
Normalized Income
-2,480.1940
-3,171.4360
-3,318.1740
-90.6700
-426.4490
Interest Expense
--
3.1620
2.1030
--
48.3900
Net Interest Income
-0.8380
-3.1620
-2.1030
--
-48.3900
EBIT
-2,480.7060
-3,168.2740
-3,169.6330
-90.6700
-42.4800
EBITDA
-2,385.8200
-3,063.0160
-3,095.5510
-90.6700
-42.4800
Reconciled Cost of Revenue
257.7980
126.0920
19.2140
--
--
Reconciled Depreciation
94.8860
105.2580
74.0820
--
--
Net Income from Continuing Operation Net Minority Interest
-2,480.1940
-3,171.4360
-3,171.7360
-90.6700
-90.8700
Total Unusual Items Excluding Goodwill
--
--
146.4380
--
335.5790
Total Unusual Items
--
--
146.4380
--
335.5790
Normalized EBITDA
-2,385.8200
-3,063.0160
-3,241.9890
-90.6700
-378.0590
Tax Rate for Calcs
--
0.0001
--
--
--
12/31/2020 - 10/24/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ESLAW Estrella Immunopharma, Inc.
0.0910
-0.11%
 
SBMFF Sino Biopharmaceutical Limited
0.4110
0.00%
 
INTI Inhibitor Therapeutics, Inc.
0.0600
0.00%
 
MBXBF Microbix Biosystems Inc.
0.2978
-1.03%
 
MRES Institute of Biomedical Research Corp.
0.0230
+74.24%
 
ACHFF Arch Biopartners Inc.
1.3300
0.00%
 
EMMA Emmaus Life Sciences, Inc.
0.0140
0.00%
 
KRBP Kiromic BioPharma, Inc.
0.9250
0.00%
 
ESLA Estrella Immunopharma, Inc.
1.1900
+6.25%
 
ATNFW 180 Life Sciences Corp.
0.0100
-4.76%